Source: Annual Congress 2010 - Actual challenges in thoracic surgery



Rating:

Share or cite this content

Citations should be made in the following way:
P. Sardari Nia, Y. Dockx, A. Cogen, P. Lauwers, J. Hendriks, D. Subotic, P. Van Schil (Belgium; Belgrade, Republic Of Serbia). Validation of the prognostic value of growth pattern classification in operated non-small cell lung cancer (NSCLC). Eur Respir J 2010; 36: Suppl. 54, 174

Member's Comments

No comment yet.

Related content which might interest you: Prognostic value of ERCC1 expression in advanced non-small cell lung cancer (NSCLC) Source: Annual Congress 2012 - Prognosis of lung cancer Year: 2012 FEV1 is not a prognostic marker in operated patients with stage I or II non-small cell lung cancer (NSCLC) Source: Annual Congress 2011 - Surgery for lung cancer: pre-operative evaluation and results Year: 2011 Analysis of the prognosis value of the mitochondrial activity in resected non-small cell lung cancer (NSCLC) Source: Annual Congress 2010 - Prognostic factors for lung cancer Year: 2010 Prognostic value of comorbidity in operated non-small cell lung cancer Source: Eur Respir J 2006; 28: Suppl. 50, 763s Year: 2006 Tumour metabolic-flow difference as a potential predictor of survival in non-small cell lung cancer (NSCLC) Source: Annual Congress 2010 - Staging of lung cancer Year: 2010 Analysis of survival and characteristics of patients with non-small cell lung carcinoma (NSCLC) stage IV depending on molecular markers Source: International Congress 2019 – Biology and prognosis of lung cancer Year: 2019 Evaluation of the role of EGFR as prognostic factor in stage III non-small cell lung cancer (NSCLC): a retrospective analysis Source: Eur Respir J 2004; 24: Suppl. 48, 478s Year: 2004 A novel biologic classification of non-small cell lung cancer Source: Annual Congress 2005 - New insights into prognosis in thoracic surgical oncology Year: 2005 24h-blood profile gene expression biomarkers of the response to bevacizumab-erlotinib (BE) in advanced non-squamous non-small cell lung cancer (NSCLC) Source: International Congress 2016 – Therapeutic trials in lung cancer Year: 2016 Is Cyfra 21-1 serum level predictive for the type of response to treatment or survival in locally advanced and metastatic non-small cell lung cancer (NSCLC)? Source: Eur Respir J 2004; 24: Suppl. 48, 76s Year: 2004 Prognostic parameters in non-small cell lung cancer (211 cases) Source: Eur Respir J 2002; 20: Suppl. 38, 268s Year: 2002 Prevalence of silent brain metastasis (BM) in the initial staging of non-small cell lung carcinoma (NSCLC) Source: Annual Congress 2011 - Imaging, functional evaluation and staging for lung cancer patients Year: 2011 Prognostic value of apoptotic index (AI) considered jointly with cell cycle regulators in non-small cell lung cancer (NSCLC) Source: Eur Respir J 2006; 28: Suppl. 50, 387s Year: 2006 Predictive role of plasmatic biomarkers in advanced non-small cell lung cancer (NSCLC) treated with nivolumab (nivo). Source: International Congress 2018 – Lung cancer: new aspects in diagnosis and management Year: 2018 The prognostic significance of sVEGF levels in patients(pts) with Non-small cell lung cancer (NSCLC) Source: Eur Respir J 2003; 22: Suppl. 45, 363s Year: 2003 Characterization of patients with non-small cell lung cancer (NSCLC) relative to its EGFR mutational status Source: Annual Congress 2011 - Epidemiology of lung cancer and screening Year: 2011 Prognostic factors in patients with resected pathologic stage I and II nonsmall cell lung cancer (NSCLC) Source: Eur Respir J 2002; 20: Suppl. 38, 269s Year: 2002 Risk factor for survival in never-smokers non-small cell lung cancer (NSCLC) Source: Annual Congress 2010 - Thoracic malignancies: interesting case studies and series Year: 2010 Survival and prognostic factors of oligometastatic non-small cell lung carcinoma: A single center experience Source: International Congress 2017 – Lung cancer: important scientific reports from endoscopists and thoracic surgeons Year: 2017 TNFα as a prognostic factor in surgically treated non-small cell lung carcinomas Source: Annual Congress 2005 - Management of lung cancer: clinical problems Year: 2005